Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01352975 · ClinicalTrials.gov registry record

Study of Dark Adaptation in Age-Related Macular Degeneration

A clinical trial of Age-related Macular Degeneration, sponsored by National Eye Institute (NEI).

Active
Registry status
217
Enrollment target
1
Study location

NCT01352975: Active study of Age-related Macular Degeneration, sponsored by National Eye Institute (NEI).

NCT01352975 is a study of Age-related Macular Degeneration that is active but no longer recruiting, run by National Eye Institute (NEI). The registered enrollment target is 217 participants, below the 1,505-participant average among 74 other Age-related Macular Degeneration trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01352975, a study of Age-related Macular Degeneration, is active but no longer recruiting, sponsored by National Eye Institute (NEI).

ACTIVE NOT RECRUITING
Registry status
217 participants
Enrollment target
1
Study location

Study Summary

Background: * Age-related macular degeneration (AMD) is a leading cause of vision loss in individuals over 55 years of age. It can cause permanent loss of central vision, which is important for seeing fine details and long distances. AMD has two forms: wet AMD and dry AMD. Most people with AMD have dry AMD. But dry AMD can progress to wet AMD. Wet AMD is the more serious form and can result in severe vision loss. * A method to identify and monitor the early to middle stages of AMD may help researchers develop new treatments to stop the disease before it becomes severe. In early dry AMD, people cannot see well at night. Researchers want to study whether a procedure that measures how the eye adjusts to the dark can help to identify and monitor early to middle dry AMD. Objectives: \- To evaluate the effectiveness of using a dark adaptation protocol to identify and monitor early to middle dry age-related macular degeneration. Eligibility: \- People at least 50 years of age who have no AMD. Others who have early to middle dry AMD in at least one eye. Design: * People will be screened with a physical examination, medical history, blood and urine tests, and a full eye exam. * This study will last 5 years and require at least 9 visits to NIH. (First visit; study visits at months 3, 6, 12, 18, and 24; and 3 yearly followup visits). * Up to 10 people will be asked to come back to the clinic 1 week after their first visit. They will be asked to test the device to be used in the study. * Participants will have baseline exams. These questions will be about problems that affect their eyes under different lighting conditions. * At every visit, participants will answer questions about general health and current medications (including any vitamins or supplements). They will also have a full eye exam and a 20- to 40-minute test. This test measures how fast the eyes recover in response to decreasing levels of light. The test also measures how sensitive the eyes are to these con

Primary Outcome

mean change, including the distribution of change, in dark adaptation response

Study Locations (1)

Maryland

  • National Institutes of Health Clinical Center - Bethesda

Trial Details

FieldValue
Enrollment Target 217 participants
Start Date 2011-05-16
National Eye Institute (NEI)

221 total trials

What the registry record for NCT01352975 still lists

NCT01352975 is an observational study that tracks outcomes without assigning an intervention. The registered 217 participants enrollment target is mid-sized for trials with a published cap, below the 1,505-participant average among 74 other Age-related Macular Degeneration trials with a reported enrollment target (86% lower).

The record links to 1 condition, with Age-related Macular Degeneration appearing as the primary indexed condition, and to 0 interventions.

NCT01352975 reports a single indexed study location in Maryland.

Frequently Asked Questions

What is clinical trial NCT01352975 about?

NCT01352975 is a clinical study titled "Study of Dark Adaptation in Age-Related Macular Degeneration". Background: * Age-related macular degeneration (AMD) is a leading cause of vision loss in individuals over 55 years of age. It can cause permanent loss of central vision, which is important for seeing fine details and long distances. AMD has two forms: wet AMD and dry AMD. Most people with AMD have...

What is the current status of trial NCT01352975?

This trial is currently active not recruiting. The enrollment target is 217 participants. The study started on 2011-05-16.

What conditions does trial NCT01352975 study?

This clinical trial studies the following conditions: Age-related Macular Degeneration.

Who is sponsoring clinical trial NCT01352975?

This trial is sponsored by National Eye Institute (NEI), which has 221 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01352975 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Age-related Macular Degeneration

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01352975's enrollment target sits among peer trials

217 15th of 74 higher than 60 of 74 other Age-related Macular Degeneration trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Age-related Macular Degeneration trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05079282 · 217 participants · Phase 1

    Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma

  • NCT05470439 · 217 participants · NA

    My Interprofessional Care Team for Adherence and Research Engagement Disparities

  • NCT05981703 · 217 participants · Phase 1

    A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors

  • NCT06342258 · 217 participants · Phase 1

    COES: Curing Order Effects on Sealants

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT01352975, the US trial registry maintained by the National Library of Medicine. NCT01352975 (mid enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.